The launch of five novel orally administered disease-modifiers is set to revolutionize the multiple sclerosis (MS) market, which will more than double in value across the seven major markets from 2006 to reach $10.7 billion in 2016.
Scope of this title:
Analysis of patient potential, unmet needs and clinical trial design in multiple sclerosis
Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in multiple sclerosis, with forecasts of drug revenues to 2016
Discussion of Biogen Idecs and Tevas strategies and insight from key industry opinion leaders
Highlights of this title:
There is a significant need for a MS treatment with superior efficacy to current therapies with a less invasive and time-consuming route of administration. Novartis oral Fingolimod (FTY720) goes some way to meet these needs and represents the most highly anticipated pipeline drug since the initial launch of Tysabri in 2004. Amid an increasingly competitive first-line therapy market, our believes prospective players can gain competitive edge (and healthcare payer acceptance) by defining clear clinical differentiators in their trials. Head-to-head studies with a suitable comparator or showing benefit of add-on therapy represent two possible strategies. Biogen Idecs Rituxan (rituximab) and BioMS MBP-8298 are targeting the prevalent yet largely underserved primary progressive MS (PPMS) and secondary progressive MS (SPMS) indications. our predicts that if Rituxan and MBP-8298 launch, then strong uptake can be expected.
Reasons to order your copy:
Understand unmet needs in the multiple sclerosis market based on key opinion leader comments
Benchmark key late-stage disease-modifying multiple sclerosis compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
